4,7-Dimethyl-4-azaspiro[2.5]octane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4,7-Dimethyl-4-azaspiro[2.5]octane
• 英文别名: 4,7-dimethyl-4-azaspiro[2.5]octane
• 化学式: C₉H₁₇N
• 分子量: 139.24
• InChiKey: OJBHCIOKYBWVAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE
  申请人：SUMITOMO DAINIPPON PHARMA CO., LTD.

  公开号：US20160122319A1

  公开（公告）日：2016-05-05

  The present invention provides a cyclic aminomethyl pyrimidine derivative and a pharmaceutically acceptable salt thereof with high selectivity for dopamine D 4 receptors, which are useful for treating a disease such as attention deficit hyperactivity disorder. Specifically, a compound of formula (1) or a pharmaceutically acceptable salt thereof is provided, wherein n and m are independently 1 or 2; R a is C 1-6 alkyl group, C 3-6 cycloalkyl group, or amino group; R b is hydrogen atom, C 1-6 alkyl group or the like, provided that when R a is amino group, then R b is hydrogen atom; R c1 and R c2 are independently hydrogen atom, or C 1-6 alkyl group; R d1 and R d2 are independently hydrogen atom, fluorine atom or the like; ring Q is an optionally-substituted pyridyl group or an optionally-substituted isoquinolyl group; and the bond having a dashed line is a single or double bond.

  本发明提供了一种对多巴胺D4受体具有高选择性的环状氨基甲基嘧啶衍生物及其药用盐，可用于治疗注意力缺陷多动症等疾病。具体提供了一种公式(1)的化合物或其药用盐，其中n和m独立为1或2；Ra为C1-6烷基、C3-6环烷基或氨基；Rb为氢原子、C1-6烷基等，条件是当Ra为氨基时，Rb为氢原子；Rc1和Rc2独立为氢原子或C1-6烷基；Rd1和Rd2独立为氢原子、氟原子等；环Q为可选取代的吡啶基或可选取代的异喹啉基；且虚线表示的键为单键或双键。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：PLEXXIKON INC.

  公开号：US20140128390A1

  公开（公告）日：2014-05-08

  Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.

  本文描述了对c-kit蛋白激酶或携带任何突变的突变c-kit蛋白激酶起作用的化合物，以及制备和使用这种化合物治疗与c-kit蛋白激酶和突变c-kit蛋白激酶的异常活性相关的疾病和病状的方法。
• IMIDAZOLE DERIVATIVE
  申请人：DAINIPPON SUMITOMO PHARMA CO., LTD.

  公开号：US20150259344A1

  公开（公告）日：2015-09-17

  Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion disease, diseases associated with neuronal degeneration and the like, said therapeutic agent comprising a compound represented by Formula (I): [wherein X—Y—Z represents N—CO—NR 4A R 4B or the like; R 1 represents a phenyl group or the like; R 2A and R 2B may be the same as or different from each other and independently represent a hydrogen atom or the like; R 3A to R 3D and R 6 may be the same as or different from one another and independently represent a hydrogen atom or the like; R 4A and R 4B may be the same as or different from each other and independently represent an aryl group or the like; and n represents 1 or 2] or a pharmaceutically acceptable salt thereof and having a potent activity of regulating an α7 nicotinic acetylcholine receptor (an α7 nAChR).

  提供一种治疗剂，用于与中枢神经系统（CNS）和/或外周神经系统（PNS）的胆碱能性质相关的疾病、与平滑肌收缩相关的疾病、内分泌疾病、与神经退行性疾病等相关的疾病，所述治疗剂包括以下式（I）所表示的化合物：[其中X—Y—Z表示N—CO—NR4AR4B或类似物；R1表示苯基或类似物；R2A和R2B可以相同或不同，独立地表示氢原子或类似物；R3A到R3D和R6可以相同或不同，独立地表示氢原子或类似物；R4A和R4B可以相同或不同，独立地表示芳基或类似物；n表示1或2]或其药学上可接受的盐，具有调节α7尼古丁乙酰胆碱受体（α7 nAChR）的强效活性。
• Substituted Piperidine Compounds
  申请人：EPIZYME, INC.

  公开号：US20170362217A1

  公开（公告）日：2017-12-21

  The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
• US9732065B2
  申请人：——

  公开号：US9732065B2

  公开（公告）日：2017-08-15